TNFSF11 and rheumatoid arthritis: B lymphocyte depletion obtained by using Rituximab results in a decrease of resorption bone markers [40] and inhibition of RA induced osteoclastosis; this effect is obtained by a reduction of the number of osteoclast precursors in synovium and thus increases the ratio OPG/RANKL in serum [41] and as such could protect BMD.